Intensified regimen for advanced head and neck squamous cell carcinomas.
OBJECTIVE
To devise an intensified treatment regimen for patients with advanced, resectable head and neck squamous cell carcinomas.


METHODS
Phase I/II clinical trial consisting of perioperative cisplatin chemoradiotherapy, surgical resection, intraoperative radiotherapy, and postoperative cisplatin chemoradiotherapy.


METHODS
The Ohio State University Comprehensive Cancer Center, Columbus.


METHODS
Thirty-seven patients (median age, 63 years) with advanced oral cavity, oropharyngeal, or hypopharyngeal carcinomas.


RESULTS
The range of time at risk was 1 to 30 months (median, 21 months). Thirty of the 37 registered patients were analyzable; 11 have died (5 with distant metastases; 1 of lung carcinoma; and 5 were cancer-free); 2 experienced second primary tumors in the oral cavity (out of or adjacent to the previous radiotherapy portals). Treatment compliance was excellent (92%), morbidity was low, and excellent locoregional control was achieved.


CONCLUSIONS
The initial results are encouraging; the future strategy will intensify the systemic component of therapy based on results from concurrent laboratory studies.
Schuller
D E
DE
Department of Otolaryngology, Arthur G. James Cancer Hospital and Research Institute, Ohio State University, Columbus, USA.
Grecula
J C
JC
Gahbauer
R A
RA
Bauer
C
C
Au
J L
JL
Smith
R E
RE
Haller
J R
JR
Mountain
R E
RE
Young
D C
DC
Nag
S
S
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011879:Radiotherapy Dosage; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D002945:Cisplatin